# Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

> **NCT03225833** · PHASE1,PHASE2 · TERMINATED · sponsor: **Wave Life Sciences Ltd.** · enrollment: 61 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** WVE-120101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03225833
- **Lead sponsor:** Wave Life Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-17
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-05-11
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03225833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03225833, "Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03225833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*